Homologation de Santé Canada : LITFULOMC devient le premier traitement autorisé de l’alopécie areata sévère au Canada
Ce communiqué a été mis en ligne le 4 décembre 2023 sur le site de Pfizer. LITFULOMC (ritlécitinib), un inhibiteur de JAK3 et
LITFULO™ Receives Health Canada Approval, Becoming the First Approved Treatment for Severe Alopecia Areata in Canada
This press release was posted on Pfizer's website on December 4, 2023. A dual JAK3/TEC inhibitor, LITFULO™ (ritlecitinib) is approved for adults
Attack From Within: Living with Alopecia
We are pleased to share the “Attack from Within” alopecia patient video with you. This video follows Christal, Jen, Julia, and Sasha, as they share how alopecia affects their identity, their relationships, and their overall quality of life.